A Randomized, Double-Blind, Multicenter Study of Denosumab Compared With Zoledronic Acid (Zometa) in the Treatment of Bone Metastases in Men With Hormone-Refractory Prostate Cancer
Latest Information Update: 19 Jan 2022
At a glance
- Drugs Denosumab (Primary) ; Zoledronic acid
- Indications Bone metastases
- Focus Registrational; Therapeutic Use
- Sponsors Amgen
- 19 Jan 2022 Results (n=756) from zoledronate treatment arm, retrospectively analysing risk factors of skeletal-related events in patients with bone metastatic castration resistant prostate cancer , published in the Supportive Care in Cancer
- 19 Nov 2020 According to a BeiGene media release, the approval of XGEVA for the prevention of skeletal-related events (SREs) in patients with bone metastasis from solid tumors and MM was based on clinical results from four randomized international trials (NCT00321464, NCT00330759, NCT00321620, and NCT01345019).
- 19 Nov 2020 According to a BeiGene media release, the China National Medical Products Administration (NMPA) has approved XGEVA (denosumab) for the prevention of skeletal-related events (SREs) in patients with bone metastases from solid tumors and in patients with multiple myeloma (MM).